Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05981235 | Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors | completed | Phase 1 | 8 | Peking UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT02030860 | A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer | completed | Phase 1 | 15 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT03199586 |
| Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies |
| completed |
| Phase 1 |
| 23 |
| Novita Pharmaceuticals, Inc.INDUSTRY |
| 1 |
| Jul 20, 2025 |
| clinicaltrials |
| NCT01342354 | Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer | completed | Phase 1 / Phase 2 | 15 | University of ChicagoOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT04826003 | Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment | completed | Phase 1 | 54 | Hoffmann-La RocheINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | completed | Phase 1 | 54 | Incyte CorporationINDUSTRY | 6 | Jul 11, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT02039336 | Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC(M13DAP) | completed | Phase 1 / Phase 2 | 35 | The Netherlands Cancer InstituteOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT02230553 | Lapatinib Plus Trametinib in KRAS Mutant NSCLC(M14LTK) | completed | Phase 1 / Phase 2 | 35 | The Netherlands Cancer InstituteOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT01628640 | Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors | completed | Phase 1 | 17 | Mayo ClinicOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03781934 | A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations | completed | Phase 1 / Phase 2 | 53 | MedivirINDUSTRY | 4 | Jul 1, 2025 | clinicaltrials |
| NCT02159716 | CART-meso in Mesothelin Expressing Cancers | completed | Phase 1 | 19 | University of PennsylvaniaOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT03592888 | DC Vaccine in Pancreatic Cancer | completed | Phase 1 | 29 | University of PennsylvaniaOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT04963088 | Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)(TALENT) | completed | Phase 1 / Phase 2 | 65 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT00873275 | Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer | completed | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT05788484 | A Study of CDX-585 in Patients With Advanced Malignancies | completed | Phase 1 | 20 | Celldex TherapeuticsINDUSTRY | 1 | Jun 15, 2025 | clinicaltrials |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | completed | Phase 1 | 185 | Novartis PharmaceuticalsINDUSTRY | 7 | Jun 13, 2025 | clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT04616196 | Study of NKTR 255 in Combination With Cetuximab in Solid Tumors | completed | Phase 1 / Phase 2 | 25 | Nektar TherapeuticsINDUSTRY | 1 | Jun 8, 2025 | clinicaltrials |
| NCT05440942 | Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma | completed | Phase 1 | 28 | Peter Hosein, MDOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors(ARROW) | completed | Phase 1 / Phase 2 | 590 | Hoffmann-La RocheINDUSTRY | 13 | May 31, 2025 | clinicaltrials |
| NCT03914443 | A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma | completed | Phase 1 | 37 | National Cancer Center, JapanOTHER_GOV | 1 | May 31, 2025 | clinicaltrials |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | completed | Phase 1 / Phase 2 | 89 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT06208124 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Immuneering CorporationINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT04121286 | A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China | completed | Phase 1 | 17 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | May 20, 2025 | clinicaltrials |
| NCT04383938 | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 40 | Aprea TherapeuticsINDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT01754987 | A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective | completed | Phase 1 / Phase 2 | 5 | Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04581343 | A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients(PanCAN-SR1) | completed | Phase 1 | 10 | Pancreatic Cancer Action NetworkOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT00954525 | Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer | completed | Phase 1 | 14 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT01972737 | Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer | completed | Phase 1 | 10 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT03045497 | Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads | completed | Phase 1 | 15 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | May 2, 2025 | clinicaltrials |
| NCT04328740 | Phase 1 Study of Oral TP-1454 | completed | Phase 1 | 31 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT04495621 | MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)(C-PRECISE-01) | completed | Phase 1 / Phase 2 | 29 | Menarini GroupINDUSTRY | 7 | May 1, 2025 | clinicaltrials |
| NCT05383352 | A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas(SIRACUSA) | completed | Phase 1 | 177 | IpsenINDUSTRY | 7 | Apr 30, 2025 | clinicaltrials |
| NCT04796948 | A Study of Irinotecan Liposome in Advanced Pancreatic Cancer | completed | Phase 1 | 41 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04468607 | A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer | completed | Phase 1 | 46 | Genentech, Inc.INDUSTRY | 3 | Apr 25, 2025 | clinicaltrials |
| NCT03428958 | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | completed | Phase 1 / Phase 2 | 111 | NuCana plcOTHER | 3 | Apr 23, 2025 | clinicaltrials |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | completed | Phase 1 / Phase 2 | 64 | Imugene LimitedINDUSTRY | 7 | Apr 16, 2025 | clinicaltrials |
| NCT02990481 | A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors | completed | Phase 1 | 38 | Toray Industries, IncINDUSTRY | 2 | Apr 16, 2025 | clinicaltrials |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | completed | Phase 1 | 269 | ExelixisINDUSTRY | 9 | Apr 4, 2025 | clinicaltrials |
| NCT03597581 | A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer | completed | Phase 1 | 89 | Inspirna, Inc.INDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT05379790 | Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin | completed | Phase 1 | 20 | Erasmus Medical CenterOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT04761614 | Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 13 | Ning JinOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 407 | Taiho Oncology, Inc.INDUSTRY | 13 | Mar 27, 2025 | clinicaltrials |
| NCT00059930 | Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer | completed | Phase 1 | 38 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 26, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jul 31, 2025source: clinicaltrials